ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.10 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-11-13
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-09-30 was $0.00.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-06-30 was $3.20M.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $900.00K.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $267.00K, a 48.33% increase year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $78.00K, a 7700.00% increase from fiscal 2016.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $1.00K, a 99.26% decline from fiscal 2015.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $135.00K, a 71.40% decline from fiscal 2014.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2014 was $472.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.20M derived: sum of 2 quarters · filed 2023-11-13 | $4.10M 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $4.10M 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $900.00K 10-Q · filed 2023-05-12 | ||||
| 2020-09-30 | $267.00K 10-Q · filed 2020-11-19 | $465.00K derived: sum of 2 quarters · filed 2020-11-19 | $663.00K 10-Q · filed 2020-11-19 | ||
| 2020-06-30 | $198.00K 10-Q · filed 2020-08-11 | $396.00K derived: sum of 2 quarters · filed 2020-08-11 | |||
| 2020-03-31 | $198.00K 10-Q · filed 2020-05-12 | ||||
| 2019-09-30 | $180.00K 10-Q · filed 2020-11-19 | $360.00K derived: sum of 2 quarters · filed 2020-11-19 | $556.00K 10-Q · filed 2020-11-19 | ||
| 2019-06-30 | $180.00K 10-Q · filed 2020-08-11 | $376.00K derived: sum of 2 quarters · filed 2020-08-11 | |||
| 2019-03-31 | $196.00K 10-Q · filed 2020-05-12 | ||||
| 2017-12-31 | $78.00K 10-K/A · filed 2018-08-20 | ||||
| 2016-12-31 | $1.00K 10-K/A · filed 2018-08-20 | ||||
| 2015-12-31 | $135.00K 10-K/A · filed 2018-08-20 | ||||
| 2014-12-31 | $472.00K 10-K · filed 2017-02-24 | $217.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |